Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2017 July ; 26(7): 1158–1159. doi:10.1158/1055-9965.EPI-17-0307.

REPLY: Telomere length and pancreatic cancer risk—Letter

Samuel O. Antwi¹, Lisa Boardman², and Gloria M. Petersen^{2,3}

¹Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL

²Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN

³Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN

Response

Our report¹ showed that genetic risk scores computed from polymorphic variants previously associated with inter-individual variation in leukocyte telomere length^{2–4} are not associated with risk of pancreatic cancer (pancreatic ductal adenocarcinoma). Consistent with our finding, a recent meta-analysis that used methods similar to ours (published while our manuscript was under review) found no association between genetically predicted telomere length and pancreatic cancer risk.⁵ We are not aware of any other published reports on the association between genetically predicted telomere length and pancreatic cancer risk.

The author referred to a study by Lynch and colleagues⁶ and others^{7, 8} and concluded that longer telomere length is associated with an increase in risk of pancreatic cancer. We would like to point out that while Lynch *et al.* directly measured leukocyte telomere length using monochrome quantitative multiplex polymerase chain reaction (PCR),⁶ we used genotypes to predict telomere length, as has been done by others.^{5, 9} Therefore, the two studies are not directly comparable. Measured telomere length reflects inherited genetic factors, aging, lifestyle (e.g., tobacco smoking), and chronic conditions, such as diabetes mellitus.¹⁰ Our study sought to delineate the role of the genetic component alone, which is estimated to account for up to 80% of inter-individual differences in telomere length.¹⁰ The study by Lynch *et al.* would have reflected the genetic and the environmental components, age-related telomere attrition, and effect of other exposures that influence telomere length. It should be noted, however, that results from studies involving measured leukocyte telomere length have varied widely.

In contrast to Lynch *et al.*, who studied Finnish males who smoked five or more cigarettes a day⁶, Bao *et al.* recently performed a pooled analysis of five prospective studies in the United States and found that short, rather than long, leukocyte telomere length is associated with an increase in risk of pancreatic cancer in a dose-response fashion.¹¹ Further, a prospective cohort study in China found a “U-shaped” association between leukocyte

Corresponding author: Gloria M. Petersen, Mayo Clinic, 200 First Street SW, Charlton 6-243, Rochester, MN 55905. Phone: 150-7538-1563; Fax: 150-7266-2478; petersen.gloria@mayo.edu.

Conflict of interest: The authors have no conflict of interest related to this work

telomere length and pancreatic cancer risk,¹² as did a clinic-based case-control in the United States.¹³ A study of the European Prospective Investigation into Cancer and Nutrition (EPIC) found no significant association between leukocyte telomere length and pancreatic cancer; however, in a secondary analysis using cubic spline regression, the investigators found evidence for a non-linear relationship.¹⁴

While it is plausible that leukocyte telomere length represents an integrative molecular marker of exposure to risk factors for pancreatic cancer, the current evidence precludes definitive conclusions. Potential reasons for the discrepancy in study findings have been discussed.¹ We agree that the potential roles of telomerase and survivin in telomere lengthening and inhibition of apoptosis to promote carcinogenesis should be explored further in both tumor-based and blood-based studies for new insights into telomere dynamics in pancreatic cancer.

References

1. Antwi SO, Bamlet WR, Broderick BT, et al. Genetically predicted telomere length is not associated with pancreatic cancer risk. *Cancer Epidemiology Biomarkers & Prevention*. 2017
2. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. *Nat Genet*. 2013; 45:422–427. 427e421–422. [PubMed: 23535734]
3. Pooley KA, Bojesen SE, Weischer M, et al. A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. *Hum Mol Genet*. 2013; 22:5056–5064. [PubMed: 23900074]
4. Mangino M, Hwang SJ, Spector TD, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. *Hum Mol Genet*. 2012; 21:5385–5394. [PubMed: 23001564]
5. Haycock PC, Burgess S, Nounu A, et al. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. *JAMA Oncol*. 2017
6. Lynch SM, Major JM, Cawthon R, et al. A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. *Int J Cancer*. 2013; 133:2672–2680. [PubMed: 23674344]
7. Dong H, Qian D, Wang Y, et al. Survivin expression and serum levels in pancreatic cancer. *World J Surg Oncol*. 2015; 13:189. [PubMed: 26016480]
8. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. *Exp Cell Res*. 2005; 305:300–311. [PubMed: 15817155]
9. Zhang C, Doherty JA, Burgess S, et al. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. *Hum Mol Genet*. 2015; 24:5356–5366. [PubMed: 26138067]
10. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science*. 2015; 350:1193–1198. [PubMed: 26785477]
11. Bao Y, Prescott J, Yuan C, et al. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. *Gut*. 2016
12. Zhang R, Zhao J, Xu J, Liu F. Association of peripheral leukocyte telomere length and its variation with pancreatic cancer and colorectal cancer risk in Chinese population. *Oncotarget*. 2016; 7:38579–38585. [PubMed: 27509261]
13. Skinner HG, Gangnon RE, Litzelman K, et al. Telomere length and pancreatic cancer: a case-control study. *Cancer Epidemiol Biomarkers Prev*. 2012; 21:2095–2100. [PubMed: 23093543]

14. Campa D, Mergarten B, De Vivo I, et al. Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study. *Cancer Epidemiol Biomarkers Prev.* 2014; 23:2447–2454. [PubMed: 25103821]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript